ClearNote Health Names Keegan CEO as Mullarkey Steps Down
Event summary
- Kevin Keegan, current president and COO, appointed CEO effective July 31, 2026.
- Dave Mullarkey steps down after 4.5 years as CEO but remains as advisor and board member.
- Company raised $52M in Series D financing within the past year.
- ClearNote Health launched enhanced pancreatic cancer detection test recently.
The big picture
ClearNote Health's leadership transition comes as the company scales commercial operations following a $52M Series D round. The move reflects a common pattern in biotech where founders or long-term CEOs step aside to allow operational executives to drive market expansion. Keegan's extensive diagnostics background suggests a focus on scaling existing products while potentially exploring new partnerships, particularly given the company's inclusion in the National Cancer Institute's Vanguard Study.
What we're watching
- Commercial Expansion
- How Keegan will accelerate global adoption of Avantect tests and Virtuoso platform.
- Clinical Execution
- Whether the company can sustain momentum in clinical studies under new leadership.
- Strategic Continuity
- The pace at which ClearNote Health integrates Keegan's operational experience into its growth strategy.
Related topics